{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T20:06:32Z","timestamp":1763755592739,"version":"3.45.0"},"reference-count":26,"publisher":"Oncology Nursing Society (ONS)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Journal of Oncology Nursing"],"published-print":{"date-parts":[[2002,11,1]]},"DOI":"10.1188\/02.cjon.323-331","type":"journal-article","created":{"date-parts":[[2007,8,23]],"date-time":"2007-08-23T10:43:20Z","timestamp":1187865800000},"page":"323-331","source":"Crossref","is-referenced-by-count":4,"title":["Systemic Candida Infections in Patients With Leukemia: An Overview of Drug Therapy"],"prefix":"10.1188","volume":"6","author":[{"given":"Jane L.","family":"Blash","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1302","published-online":{"date-parts":[[2007,2,13]]},"reference":[{"key":"E00001","doi-asserted-by":"crossref","unstructured":"Benedict, S., & Colagreco, J. (1994). Fungal infections associated with malignancies, treatments, and AIDS. <i>Cancer Nursing, 17<\/i>, 411-417.","DOI":"10.1097\/00002820-199410000-00006"},{"key":"E00002","unstructured":"Bristol-Myers Squibb Co. (1999). Amphotericin B for injection, USP [Package insert]. Princeton, NJ: Author."},{"key":"E00003","doi-asserted-by":"crossref","unstructured":"Camp, M.J., Wingard, J.R., Gilmore, C.E., Lin, L.S., Dix, S.P., Davidson, T.G., et al. (1998). Efficacy of low-dose dopamine in preventing amphotericin B nephrotoxicity in bone marrow transplant patients and leukemia patients. <i>Antimicrobial Agents and Chemotherapy, 42<\/i>, 3103-3106.","DOI":"10.1128\/AAC.42.12.3103"},{"key":"E00004","doi-asserted-by":"crossref","unstructured":"Dismukes, W.E. (2000). Introduction to antifungal drugs. <i>Clinical Infectious Diseases, 30<\/i>, 653-657.","DOI":"10.1086\/313748"},{"key":"E00005","unstructured":"Ernst, E.J. (2001). Investigational antifungal agents. <i>Pharmacotherapy, 21<\/i>(8 Pt. 2), 165S-174S. Fujisawa Healthcare, Inc. (2000). AmBisome\u00ae for injection [Package insert]. Deerfield, IL: Author. Garber, G. (2001). An overview of fungal infections. <i>Drugs<\/i>, <i>61<\/i>(Suppl. 1), 1-12."},{"key":"E00006","unstructured":"Graybill, J.R., Kauffman, C.A., & Patel, R. (1999). Treatment of systemic fungal infections. <i>Patient Care, 33<\/i>(19), 50-72."},{"key":"E00007","doi-asserted-by":"crossref","unstructured":"Hoffman, H.L., & Pfaller, M.A. (2001). In vitro antifungal susceptibility testing. <i>Pharmacotherapy, 21<\/i>(8 Pt. 2), 111S-123S.","DOI":"10.1592\/phco.21.12.111S.34510"},{"key":"E00008","unstructured":"Holtzclaw, B.J. (1990). Control of febrile shivering during amphotericin B therapy. <i>Oncology Nursing Forum, 17<\/i>, 521-524."},{"key":"E00009","unstructured":"Holtzclaw, B.J., & Rutledge, D.N. (1990). Use of amphotericin B in immunosuppressed patients with cancer. Part two: Pharmacodynamics and nursing implications. <i>Oncology Nursing Forum, 17<\/i>, 737-742."},{"key":"E00010","unstructured":"Janssen Pharmaceutica N.V. (2001). Itraconazole oral solution\u2014Sporanox\u00ae [Package insert]. Beerse, Belgium: Author."},{"key":"E00011","doi-asserted-by":"crossref","unstructured":"Klepser, M.E. (2001). Antifungal resistance among <i>Candida<\/i> species. <i>Pharmacotherapy<\/i>, <i>21<\/i>(8 Pt. 2), 124S-132S.","DOI":"10.1592\/phco.21.12.124S.34511"},{"key":"E00012","doi-asserted-by":"crossref","unstructured":"Kontoyiannis, D.P. (2001). A clinical perspective for the management of invasive fungal infections: Focus on IDSA guidelines. <i>Pharmaco-therapy, 21<\/i>(8 Pt. 2), 175S-187S.","DOI":"10.1592\/phco.21.12.175S.34506"},{"key":"E00013","doi-asserted-by":"crossref","unstructured":"Lewis, R.E., & Kontoyiannis, D.P. (2001). Rationale for combination antifungal therapy. <i>Pharmacotherapy, 21<\/i>(8 Pt. 2), 149S-164S.","DOI":"10.1592\/phco.21.12.149S.34505"},{"key":"E00014","unstructured":"Liposome Co., Inc. (1999). Amphotericin B lipid complex injection\u2014Abelcet\u00ae [Package insert]. Princeton, NJ: Author."},{"key":"E00015","unstructured":"Medical Economics Company. (2001). Ancobon capsules (ICN). <i>Physicians' Desk Reference Electronic Library.<\/i> Montvale, NJ: Author."},{"key":"E00016","doi-asserted-by":"crossref","unstructured":"Meis, J.F., & Verweij, P.E. (2001). Current management of fungal infections. <i>Drugs, 61<\/i>(Suppl. 1), 13-25.","DOI":"10.2165\/00003495-200161001-00002"},{"key":"E00017","unstructured":"Merck & Co., Inc. (2001). Caspofungin acetate for injection\u2014Cancidas\u00ae [Package insert]. Whitehouse Station, NJ: Author."},{"key":"E00018","doi-asserted-by":"crossref","unstructured":"O'Marcaigh, A.S., & Betcher, D.L. (1994). Amphotericin B and its lipid formulations. <i>Journal of Pediatric Oncology Nursing, 11<\/i>, 125-127.","DOI":"10.1177\/104345429401100308"},{"key":"E00019","unstructured":"Pfizer Inc. (1998). Fluconizole tablets, injections and oral suspension\u2014Diflucan\u00ae [Package insert]. New York: Author."},{"key":"E00020","unstructured":"Rex, J.H., Walsh, T.J., & Anaissie, E.J. (1998). Fungal infections in iatrogenically compromised hosts. In R.W. Schrier (Ed.), <i>Advances in Internal Medicine<\/i> (pp. 321-371). St. Louis: Mosby."},{"key":"E00021","doi-asserted-by":"crossref","unstructured":"Rex, J.H., Walsh, T.J., Sobel, J.D., Filler, S.G., Pappas, P.G., Dismukes, W.E., et al. (2000). Practice guidelines for the treatment of candidiasis. <i>Clinical Infectious Diseases, 30<\/i>, 662-678.","DOI":"10.1086\/313749"},{"key":"E00022","unstructured":"Rutledge, D.N., & Holtzclaw, B.J. (1990). Use of amphotericin B in immunosuppressed patients with cancer. Part one: Pharmacology and toxicities. <i>Oncology Nursing Forum, 17<\/i>, 731-736."},{"key":"E00023","doi-asserted-by":"crossref","unstructured":"Shelton, B.K. (2000). Opportunistic fungal infections in the critically ill. <i>Critical Care Nursing Clinics of North America, 12<\/i>, 323-340.","DOI":"10.1016\/S0899-5885(18)30098-4"},{"key":"E00024","doi-asserted-by":"crossref","unstructured":"Sobel, J.D. (2000). Practice guidelines for the treatment of fungal infections. <i>Clinical Infectious Diseases, 30<\/i>, 652.","DOI":"10.1086\/313746"},{"key":"E00025","doi-asserted-by":"crossref","unstructured":"Walsh, T.J., Pappas, P., Winston, D.J., Lazarus, H.M., Petersen, F., Raffalli, J., et al. (2002). Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. <i>New England Journal of Medicine, 346<\/i>, 225-234.","DOI":"10.1056\/NEJM200201243460403"},{"key":"E00026","doi-asserted-by":"crossref","unstructured":"Wright, J.M. (1997). Antifungals: Use in high-risk patients. <i>Critical Care Nursing Quarterly, 20<\/i>(3), 12-20.","DOI":"10.1097\/00002727-199711000-00003"}],"container-title":["Clinical Journal of Oncology Nursing"],"original-title":[],"link":[{"URL":"http:\/\/ons.metapress.com\/index\/E150167564066R4L.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:54:04Z","timestamp":1763754844000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ons.org\/publications-research\/cjon\/6\/6\/systemic-candida-infections-patients-leukemia-overview-drug-therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,11,1]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2002,11,1]]}},"alternative-id":["E150167564066R4L"],"URL":"https:\/\/doi.org\/10.1188\/02.cjon.323-331","relation":{},"ISSN":["1092-1095","1538-067X"],"issn-type":[{"type":"print","value":"1092-1095"},{"type":"electronic","value":"1538-067X"}],"subject":[],"published":{"date-parts":[[2002,11,1]]}}}